Galectin Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Galectin Therapeutics

14/11/2024 14:16

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -24 cents.  The lone analyst forecast
for the quarter was for a loss of 20 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Galectin Therapeutics Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * The company reported a quarterly loss of $11.24 million.
    * Galectin Therapeutics Inc shares had risen by 5.5% this
quarter and gained 74.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 17.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Galectin
Therapeutics Inc is 11.00 
This summary was machine generated from LSEG data November 14 at
02:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.20          -0.18          Beat
 Jun. 30 2024      -0.16          -0.20          Missed
 Mar. 31 2024      -0.16          -0.19          Missed
 Dec. 31 2023      -0.16          -0.16          Met